PMID- 19690248
OWN - NLM
STAT- MEDLINE
DCOM- 20090909
LR  - 20171116
IS  - 1526-7598 (Electronic)
IS  - 0003-2999 (Linking)
VI  - 109
IP  - 3
DP  - 2009 Sep
TI  - Ketamine inhibits maturation of bone marrow-derived dendritic cells and priming 
      of the Th1-type immune response.
PG  - 793-800
LID - 10.1213/ane.0b013e3181adc384 [doi]
AB  - BACKGROUND: Dendritic cells (DCs) play a key role as antigen-presenting cells and 
      growing evidence suggests that DCs influence T-cell activation and regulate the 
      polarity of the immune response. Ketamine has been reported to have 
      immunomodulatory properties that affect immune cells, including macrophages and 
      natural killer cells. However, the effect of ketamine on DCs has not been 
      characterized. We examined the immunomodulation of DCs by ketamine. METHODS: We 
      used bone marrow-derived DCs induced by granulocyte-monocyte-colony stimulating 
      factor and interleukin (IL)-4 from bone marrow and analyzed the expression of 
      costimulatory molecules (CD40, CD80, and CD86), major histocompatibility complex 
      class II molecules, and secretion of IL-12p40. Furthermore, we evaluated the 
      immune response in mixed cell cultures of DCs and T cells and the contact 
      hypersensitivity response in a whole animal. RESULTS: Ketamine suppressed the 
      expression of CD40, CD80, and major histocompatibility complex class II molecules 
      in DCs. DCs treated with ketamine also secreted less IL-12p40 and displayed 
      greater endocytosis. In mixed cell cultures with CD4+ T cells and DCs, 
      ketamine-treated DCs showed less propensity to stimulate the proliferation of 
      CD4+ T cells and the secretion of interferon from CD4+ T cells. Furthermore, 
      ketamine-treated DCs impaired the induction of a cell-mediated immune response. 
      CONCLUSION: Our findings suggest that ketamine inhibits the functional maturation 
      of DCs and interferes with DC induction of Th1 immunity in the whole animal. 
      These novel findings provide new insight into the immunopharmacological role of 
      ketamine.
FAU - Ohta, Noriyuki
AU  - Ohta N
AD  - Intensive Care Unit, Osaka University Hospital, Osaka, Japan. 
      nohta753@hp-icu.med.osaka-u.ac.jp
FAU - Ohashi, Yoshifumi
AU  - Ohashi Y
FAU - Fujino, Yuji
AU  - Fujino Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Anesthetics, Dissociative)
RN  - 0 (B7-1 Antigen)
RN  - 0 (B7-2 Antigen)
RN  - 0 (CD40 Antigens)
RN  - 207137-56-2 (Interleukin-4)
RN  - 690G0D6V8H (Ketamine)
SB  - IM
MH  - Anesthetics, Dissociative/*pharmacology
MH  - Animals
MH  - B7-1 Antigen/biosynthesis
MH  - B7-2 Antigen/biosynthesis
MH  - Bone Marrow Cells/*cytology/drug effects/metabolism
MH  - CD40 Antigens/biosynthesis
MH  - Dendritic Cells/*cytology
MH  - Female
MH  - Interleukin-4/metabolism
MH  - Ketamine/*pharmacology
MH  - Macrophages/metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Th1 Cells/*cytology/drug effects
EDAT- 2009/08/20 09:00
MHDA- 2009/09/10 06:00
CRDT- 2009/08/20 09:00
PHST- 2009/08/20 09:00 [entrez]
PHST- 2009/08/20 09:00 [pubmed]
PHST- 2009/09/10 06:00 [medline]
AID - 109/3/793 [pii]
AID - 10.1213/ane.0b013e3181adc384 [doi]
PST - ppublish
SO  - Anesth Analg. 2009 Sep;109(3):793-800. doi: 10.1213/ane.0b013e3181adc384.